[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-351115-105":59,"doc-detail-351115-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","homologous-recombination-deficiency-in-newly-diagnosed-advanced-ovarian-cancer-across-nine-middle-east-countries-prevalence-real-world-testing-pathways-and-treatment-implications","Homologous recombination deficiency in newly diagnosed advanced ovarian cancer across nine Middle East countries - Prevalence, real-world testing pathways, and treatment implications","","Background addresses homologous recombination deficiency (HRD) as a predictive and prognostic biomarker in high-grade serous/endometrioid ovarian cancers and related tumors, using the HALO study (NCT04991051) to evaluate HRD prevalence across Asia, Middle East and Africa (MEA), and Russia. Methodology describes a cross-sectional, non-interventional MEA cohort enrolling patients with newly diagnosed stage III/IV disease with tumor blocks collected within 120 days. Logistic regression models risk factors for HRD positivity and tumor BRCA alterations. Results report substantial HRD positivity, genomic instability patterns, BRCA-related findings, and treatment pathway observations.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/homologous-recombination-deficiency-in-newly-diagnosed-advanced-ovarian-cancer-across-nine-middle-east-countries-prevalence-real-world-testing-pathways-and-treatment-implications/351115/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/homologous-recombination-deficiency-in-newly-diagnosed-advanced-ovarian-cancer-across-nine-middle-east-countries-prevalence-real-world-testing-pathways-and-treatment-implications/351115.png","ImageObject",300,407,{"name":92,"@type":93},"Miles","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-26","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the HALO study designed to evaluate regarding HRD?","Question",{"text":112,"@type":113},"The HALO study evaluated the prevalence of homologous recombination deficiency (HRD) across HGSOC/HGEOC, primary peritoneal cancer, and fallopian tube cancer in Asia, the Middle East and Africa, and Russia.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which patient group and sample collection timeframe were used in the MEA subset?",{"text":117,"@type":113},"The MEA subset enrolled patients with newly diagnosed stage III/IV disease (FIGO classification) and used formalin-fixed paraffin-embedded tumor blocks collected within 120 days of enrolment.",{"name":119,"@type":110,"acceptedAnswer":120},"How did the study measure HRD-related genomic instability and BRCA alterations?",{"text":121,"@type":113},"Primary endpoints included HRD prevalence, genomic instability excluding tumor BRCA mutations (tBRCAm), and tBRCAm; logistic regression then assessed risk factors for HRD positivity and tBRCAm.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},351115,1790868965,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":19,"preview_urls":145},13056703019404,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Shash etal. BMC Cancer (2026) 26:296 BMC Cancer  \n[https://doi.org/10.1186/s12885-025-15537-3](https://doi.org/10.1186/s12885-025-15537-3)  \nRESEARCH Open Access  \nHomologous recombination deficiency  in newly diagnosed advanced ovarian cancer across nine Middle East countries: prevalence, real-world testing pathways, and treatment implications  \nEmad Shash1,2*, Mehemet Ali Vardar3, Cagatay Taskiran4, Salha Boujassoum5, Jamila Riromar6, Ahmed Aboutaleb7, Farah Sadek7, Eman Samy7 and Waleed Bahaj8  \nAbstract  \nBackground With current evidence of homologous recombination deficiency (HRD) emerging as a predictive and prognostic biomarker in high-grade serous/endometrioid ovarian cancers (HGSOC/HGEOC), the HALO study (NCT04991051) evaluated the prevalence ofthe HRD in patients with HGSOC/HGEOC, primary peritoneal cancer (PPC), and fallopian tube cancer (FTC) across Asia, Middle East and Africa (MEA), and Russia.  \nMethodology The MEA subset of this cross-sectional, non-interventional study enrolled patients with newly diagnosed stage III/IV (International Federation of Gynaecology and Obstetrics [FIGO] classification) HGSOC/HGEOC, PPC, FTC during May 2021-Jan 2022 with formalin-fixed paraffin-embedded tumour block(s) collected within 120 days of enrolment. Primary endpoints included prevalence of HRD, genomic instability (GI) excluding tumour BRCA mutations (tBRCAm), and tBRCAm. Logistic regression model predicted the risk factors associated with HRD positivity and tBRCAm.  \nResults Of 195 patients (median [range] age, 58.2 [24 .0-89. 0] years), 88. 7% had primary ovarian tumour. The HRD status was analysed in 180 patients; 52 . 2%(94/180) were HRD positive – 23 . 9%(43/180) had high GI scores excluding tBRCA1/2m, and 28. 3%(51/180) had tBRCAm. More than two-thirds (71 . 3%) of patients underwent debulking surgery, 45,1% received neoadjuvant and 50. 8% received adjuvant therapy. No patients received PARPi therapy. In univariate analysis, nulliparity was associated with lower odds of HRD positivity (odds ratio [OR]: 0 . 27, p=0 . 003) . Family history (OR: 0 . 39, p=0 . 02) and nulliparous women (OR: 0 . 19, p=0 . 03) were associated with lower odds of high GI score. Higher odds oftBRCAm were observed in ex-smokers (OR: 6 . 77, p=0 . 02), family history (OR: 3 . 11, p=0 . 0009), and surgicallyresected tissue (OR: 2 . 00, p=0 . 04); lower odds in patients with FIGO stage IV (OR: 0 . 26, p=0 . 004) . In multivariate  \n*Correspondence:  \nEmad Shash[emad.shash@nci.cu.edu.eg](emad.shash@nci.cu.edu.eg)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/licenses/by-nc-nd/4.0/](vecommons.org/licenses/by-nc-nd/4.0/.)[.](vecommons.org/licenses/by-nc-nd/4.0/.)  \nShash et al. BMC Cancer (2026) 26:296 Page 2 of 12  \nanalysis, h/o genetic-related cancer (OR: 3 . 75, p=0 . 002), h/o contraceptive use (OR: 5 . 19, p=0 . 009) was associated with higher odds oftBRCA1m whereas FIGO stage IV disease (OR: 0 . ","cbCaidvxQyvUu9Cb","https://ap.wps.com/l/cbCaidvxQyvUu9Cb","pdf",1879511,12,"English","# Abstract\n## Background\n## Methodology\n## Results\n## Conclusion\n# Introduction","[{\"question\":\"What was the HALO study designed to evaluate regarding HRD?\",\"answer\":\"The HALO study evaluated the prevalence of homologous recombination deficiency (HRD) across HGSOC/HGEOC, primary peritoneal cancer, and fallopian tube cancer in Asia, the Middle East and Africa, and Russia.\"},{\"question\":\"Which patient group and sample collection timeframe were used in the MEA subset?\",\"answer\":\"The MEA subset enrolled patients with newly diagnosed stage III/IV disease (FIGO classification) and used formalin-fixed paraffin-embedded tumor blocks collected within 120 days of enrolment.\"},{\"question\":\"How did the study measure HRD-related genomic instability and BRCA alterations?\",\"answer\":\"Primary endpoints included HRD prevalence, genomic instability excluding tumor BRCA mutations (tBRCAm), and tBRCAm; logistic regression then assessed risk factors for HRD positivity and tBRCAm.\"}]","Homologous recombination deficiency in newly diagnosed advanced ovarian cancer across nine Middle East countries - Prevalence, real-world testing pathways, and treatment implications | PDF",1790092677,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0275d9ecf1074deb970db7197f4070ce.webp",983,1310,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9bff255724224ad456925ff8bfe686bc.webp",982,1309,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ce08174c5303ed584a955e3f8996780d.webp",981,1308,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1744f0437b073320a073736684d4efea.webp",980,1306]